TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum ) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica , or Cannabis ruderalis , optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
1 . A method for treating, alleviating, or ameliorating one or more symptoms associated with a mood disorder, the method comprising administering a pharmaceutical dosage form comprising:
0.1 mg to 10 mg of psilocin, psilocybin, salts thereof, or combinations thereof; and
one or more pharmaceutically acceptable excipients selected from carriers, fillers, binders, disintegrants, preservatives, or antioxidants.
2 . The method of claim 1 , wherein the pharmaceutical dosage form comprises 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5, mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg of psilocybin or psilocin.
3 . The method of claim 1 , wherein the wherein the psilocin, psilocybin, salts thereof, or combinations thereof are:
(a) pure compounds;
(b) from mushroom species comprising psilocybin, psilocin, salts thereof, or combinations thereof; or
(c) from extracts of mushroom species comprising psilocybin, psilocin, salts thereof;
combinations thereof.
4 . The method of claim 1 , wherein the pharmaceutical dosage form further comprises 10 μg to 200 mg of niacin.
5 . The method of claim 1 further comprising acidifying agents, alkalizing agents, antifoaming agents, sweetening agents, buffering agents, chelating agents, coating agents, emulsifying agents, solubilizing agents, flavoring agents, coloring agents, humectants, or a combination thereof.
6 . The method of claim 1 , wherein the administration is at a regular interval until the subject in need thereof does not require administration.
7 . The method of claim 1 , wherein the pharmaceutical dosage form is administered 1 to 6 times per day.
8 . The method of claim 1 , wherein the mood disorder comprises depression, major depressive disorder, treatment resistant depression, persistent depression, manic depression or bipolar disorder, depressive psychosis, perinatal depression, premenstrual dysphoric disorder, seasonal depression, situational depression, panic disorder, or a combination thereof.
9 . The method of claim 1 , wherein the psilocybin or psilocin bind to a neurotropin receptor.
10 . The method of claim 1 , wherein the pharmaceutical dosage form releases one or more neurotropins.
11 . The method of claim 1 , wherein the pharmaceutical dosage form enhances neuronal plasticity.
12 . A method for treating, alleviating, or ameliorating one or more symptoms associated with a psychiatric disorder, the method comprising: administering to the subject a pharmaceutical dosage form comprising:
0.1 mg to 10 mg of psilocin, psilocybin, salts thereof, or combinations thereof; and
one or more pharmaceutically acceptable excipients selected from carriers, fillers, binders, disintegrants, preservatives, or antioxidants.
13 . The method of claim 12 , wherein the wherein the psilocin, psilocybin, salts thereof, or combinations thereof are:
(a) pure compounds;
(b) from mushroom species comprising psilocybin, psilocin, salts thereof, or combinations thereof; or
(c) from extracts of mushroom species comprising psilocybin, psilocin, salts thereof;
combinations thereof.
14 . The method of claim 12 , wherein the pharmaceutical dosage form further comprises 10 μg to 200 mg of niacin.
15 . The method of claim 12 , further comprising acidifying agents, alkalizing agents, antifoaming agents, sweetening agents, buffering agents, chelating agents, coating agents, emulsifying agents, solubilizing agents, flavoring agents, coloring agents, humectants, or a combination thereof.
16 . The method of claim 12 , wherein the administration is at a regular interval until the subject in need thereof does not require administration.
17 . The method of claim 12 , wherein the pharmaceutical dosage form is administered 1 to 6 times per day.
18 . The method of claim 12 , wherein the psychiatric disorder comprises anxiety, substance abuse disorders, attention deficit/hyperactivity disorder, sleep disorders, eating disorders, schizophrenia, personality disorders, or a combination thereof.
19 . The method of claim 12 , wherein the psilocybin or psilocin bind to a neurotropin receptor.
20 . The method of claim 12 , wherein the pharmaceutical dosage form releases one or more neurotropins.